NEWS
LATEST
FULL LIST
-
CollPlant Biotechnologies Update – Reports Q3 2024 Results, Advances Regenerative Breast Implant Program
Overview and Key HighlightsREHOVOT, Israel – CollPlant Biotechnologies, a developer of non–animal-derived collagen technologies for tissue regeneration and medical aesthetics, released its third quarter 2024 financial results and provided a corporate update on November 27, 2024. Preclinical Study SuccessA key highlight of the update was the promising outcome from a preclinical study evaluating CollPlant’s commercial-scale,…
-
Vericel – Poised for Growth with Expanding Indications and Strong Margins
Vericel (NASDAQ:VCEL) has established itself as a key player in regenerative medicine, yet the market continues to undervalue its potential. Unlike biotech firms chasing high-risk blockbuster drug approvals, Vericel has built a solid foundation with FDA-approved products—MACI, Epicel, and NexoBrid—delivering steady revenue growth and strong financials. With a notable 16% year-over-year revenue increase and zero…
-
Sernova Biotherapeutics Secures FDA Clearance for Thyroid Cell Pouch IND Application
Sernova Biotherapeutics has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application. The clearance enables the company to evaluate its Cell Pouch bio-hybrid organ, integrated with autologous thyroid cells, in patients undergoing thyroid surgery for nodular thyroid disease—a condition that often leads to hypothyroidism due to reduced thyroid hormone…
-
Nurami Medical Secures $30 Million to Accelerate Meningeal Tissue Repair Innovation
Nurami Medical, a Haifa‐based biomedical startup, has closed a $30 million funding round to advance its innovative approach to meningeal tissue repair. The company, led by co-founder Nora Nseir and her partner Dr. Amir Bahar, is focused on developing products that support the regeneration of meningeal tissue following complex brain and spinal cord surgeries. The…
-
Trestle Bio Announces Research Collaboration with Humacyte
Trestle Biotherapeutics, Inc. today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical-stage company working on bioengineered kidney tissues for patients with end stage renal disease (ESRD). The collaboration will investigate potential technological synergies…
-
Xenotransplantation Advances: United Therapuetics and eGensis Companies to Watch
In a significant development for the field of xenotransplantation, two biotech companies have recently received critical regulatory approvals that could reshape the future of organ transplantation. Following early clinical successes and notable setbacks, industry leaders are now advancing clinical trials aimed at addressing the chronic shortage of human organs for transplant. The concept of xenotransplantation…
-
ARMI BioFabUSA A Catalyst for Regenerative Medicine
Bringing Biofabrication Companies Together The Advanced Regenerative Manufacturing Institute (ARMI) is leading the charge in revolutionizing the bioeconomy of the United States. As a member-based nonprofit, ARMI operates through its flagship initiative, BioFabUSA, which fosters collaboration among more than 200 partners, including corporations, academic institutions, and nonprofits. The goal: to develop scalable, consistent, and cost-effective…
-
Tissue Therapeutics: The Curative Potential of Combining Cells & Biomaterials
Introduction: Defining Tissue Therapeutics and Tissue Engineering Tissue therapeutics represents a convergence of cell therapy and biomaterials, offering advanced solutions for unmet clinical needs such as organ and tissue repair. Traditional biologics and gene therapies often fall short in providing the structural and functional support necessary for full tissue restoration. Tissue engineering is now making…
-
EU-Funded micro2MACRO Project Aims to Push Cartilage Tissue Regeneration with Bioprinting
Teltow, February 5, 2025 – A new European initiative is set to push the boundaries of tissue regeneration and bioprinting. The micro2MACRO (m2M) project, launched in December 2024, is an EU-funded effort that aims to develop a cutting-edge bioprinting platform capable of generating personalized tissue grafts for medical applications. The project brings together leading academic…
-
Auxilium Biotechnologies Achieves Bioprinting Milestone Aboard the ISS
Auxilium Biotechnologies successfully deployed its 3D bioprinter aboard the International Space Station (ISS). This achievement marks the an instance of implantable medical devices being printed in space, paving further way for advanced medical solutions both on Earth and in future space missions. Printing Medical Devices in Microgravity Auxilium Biotechnologies has successfully 3D bioprinted perfusable vasculature,…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 